Ultragenyx Pharmaceutical Inc.

RARE Healthcare Biotechnology

Ultragenyx Pharmaceutical Inc.’s revenue for fiscal 2025 (year ended December 2025) was $673.0 million, up 20.2% from fiscal 2024. In the quarter to June 2026, revenue grew 28.1%, EPS grew 23.1% and free cash flow grew 12.5%, each against the same quarter a year earlier. Revenue growth for five consecutive years.

14.54 0.63 −4.15%
Market cap
$1.5B
P/E
0.0×
Fwd P/E
−4.8×
Dividend yield
—
F-score
5/9
Altman Z
−3.57
Beneish M
−2.68
Dividend safety
n/a

A Cash Flow Statement is a financial report that details the cash inflows and outflows of a company over a specific period. It is divided into three sections: operating activities, investing activities, and financing activities. This statement helps assess the company’s liquidity, solvency, and overall financial health. By tracking cash movements, it provides insights into the company's ability to generate cash to fund operations, pay debts, and invest in growth. Businesses and investors use it to evaluate the sustainability of a company's cash flow and its financial stability.

Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17 Dec '16
Net Income
(575.00) (569.00) (607.00) (707.42) (454.02) (186.57) (402.73) (197.61) (302.14) (245.87)
Depreciation & Amortization
31.00 23.00 13.00 20.92 19.85 13.11 2.33 16.90 7.53 8.27
Non Cash Items (Other)
101.00 118.00 135.00 244.16 158.72 (63.43) 74.48 (85.06) 44.75 50.33
Accounts Receivable Change
(31.00) (34.00) (23.00) (12.07) (5.43) 9.84 (20.10) (7.58) (5.17) —
Change in inventories
(6.00) (11.00) (7.00) (9.70) (3.12) (1.35) (4.45) (5.28) (0.76) —
Accounts Payable Change
— — 2.38 87.44 32.31 26.85 13.31 3.37 3.46 2.50
Change in payables and accrued liability
24.00 47.00 (1.00) 79.85 32.31 26.85 13.31 2.36 (1.17) 32.19
Change in other assets and liabilities
(10.00) 12.00 15.00 3.80 (87.00) 69.32 (8.22) (14.28) 3.11 (8.39)
Operating Cash Flow
(466.00) (414.00) (475.00) (380.46) (338.69) (132.22) (345.38) (290.57) (253.84) (160.97)
Capital expenditures
(6.00) (7.00) (44.00) (116.12) (73.09) (43.90) (24.83) (4.08) (2.79) (10.19)
Change in intangibles (net)
(15.00) (13.00) (3.00) (30.00) — — — — — —
Net Aquisitions
— — — (75.02) — — — — (142.80) —
Short Term Investments Change (Net)
258.00 4.00 221.00 (79.75) (201.18) (172.44) 26.13 (199.58) 201.08 101.31
Long-Term Investments Change (Net)
— — — 10.09 79.84 42.78 (14.34) — — —
Other investing activities
(1.00) (2.00) (6.00) (0.84) (0.94) (5.55) — 170.32 — —
Investing cash flow
236.00 (18.00) 168.00 (291.65) (195.37) (179.12) (13.04) (33.33) 55.48 91.12
Repayment/Issuance of Debt (Net)
— — — — — — — — (4.94) —
Equity Repurchase (Common, Net)
86.00 399.00 387.00 10.81 119.04 600.51 365.07 336.85 141.21 138.68
Other financial activities
392.00 — 1.00 490.40 (0.49) (0.24) 314.23 (87.70) 62.70 55.17
Financing cash flow
478.00 399.00 388.00 501.21 118.55 600.27 679.31 336.85 136.27 138.68
Exchange Rate Adjustment
4.00 (2.00) 0.46 (1.07) (1.19) 1.12 (0.16) (0.47) 0.53 (0.06)
Change in Cash
252.00 (35.00) 81.00 (171.98) (416.71) 290.05 320.72 12.48 (61.57) 68.75
Beginning Cash
184.00 219.00 138.00 309.59 726.29 436.24 115.53 103.04 164.61 95.85
Ending Cash
436.00 184.00 219.00 137.60 309.59 726.29 436.24 115.53 103.04 164.61
Stock Based Compensation
153.00 158.00 135.00 130.38 104.95 85.74 82.00 80.11 68.01 48.31
Dividends Paid (Common)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Cash/Marketcap
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Assets Liabilities Change (Total)
(23.00) 14.00 (16.00) 61.87 (63.24) 104.66 (19.46) (24.79) (3.98) 26.30
Investments Change (Net)
258.00 4.00 221.00 (69.66) (121.34) (129.66) 11.79 (199.58) 201.08 101.31
Issuance/Purchase of Shares
86.00 399.00 387.00 10.81 119.04 600.51 365.07 336.85 141.21 138.68
Other line items
Revenue per Employee
0.49 0.43 0.34 0.28 0.31 0.30 0.14 0.08 0.01 0.00

Fold the line items

In millions of $ except per-share values · columns are period end dates